TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.
Tan G, Jin B, Qian X, Wang Y, Zhang G, Agyekum EA, Wang F, Shi L, Zhang Y, Mao Z, Shi C, Xu Y, Li X, Zhang L, Li S.
Tan G, et al. Among authors: zhang l, zhang g, zhang y.
Sci Rep. 2024 Oct 10;14(1):23719. doi: 10.1038/s41598-024-75087-9.
Sci Rep. 2024.
PMID: 39390090
Free PMC article.